BR112021016865A2 - Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103 - Google Patents
Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103Info
- Publication number
- BR112021016865A2 BR112021016865A2 BR112021016865A BR112021016865A BR112021016865A2 BR 112021016865 A2 BR112021016865 A2 BR 112021016865A2 BR 112021016865 A BR112021016865 A BR 112021016865A BR 112021016865 A BR112021016865 A BR 112021016865A BR 112021016865 A2 BR112021016865 A2 BR 112021016865A2
- Authority
- BR
- Brazil
- Prior art keywords
- wikim0103
- preventing
- liver disease
- fatty liver
- composition
- Prior art date
Links
- 241000202218 Weissella hellenica Species 0.000 title abstract 5
- 208000008589 Obesity Diseases 0.000 title abstract 4
- 208000010706 fatty liver disease Diseases 0.000 title abstract 4
- 235000020824 obesity Nutrition 0.000 title abstract 4
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 235000021109 kimchi Nutrition 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103. refere-se a uma nova cepa weissella hellenica wikim0103 isolada de kimchi e a uma composição compreendendo a mesma ou seu uso. a presente invenção apresenta um método para prevenção, melhora e tratamento de inflamação, obesidade ou doença hepática gordurosa de um indivíduo, por meio da administração da nova cepa weissella hellenica wikim0103 isolada de kimchi ou uma composição contendo a mesma. a weissella hellenica wikim0103, de acordo com a presente invenção, mostra um efeito inibitório para a produção de esteatose hepática ao inibir o acúmulo de gordura nas células hepáticas e reduzir a expressão de genes relacionados à esteatose hepática e, portanto, pode ser utilizada de várias maneiras para usos na prevenção, na melhora e no tratamento de inflamação, obesidade ou doença hepática gordurosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190024255A KR102072059B1 (ko) | 2019-02-28 | 2019-02-28 | 와이셀라 헬레니카 WiKim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
PCT/KR2020/002844 WO2020175939A1 (ko) | 2019-02-28 | 2020-02-27 | 와이셀라 헬레니카 wikim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021016865A2 true BR112021016865A2 (pt) | 2021-11-23 |
Family
ID=69369321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021016865A BR112021016865A2 (pt) | 2019-02-28 | 2020-02-27 | Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220160796A1 (pt) |
EP (1) | EP3933030A4 (pt) |
JP (1) | JP7266110B2 (pt) |
KR (1) | KR102072059B1 (pt) |
CN (1) | CN113508173A (pt) |
AU (1) | AU2020229728A1 (pt) |
BR (1) | BR112021016865A2 (pt) |
CA (1) | CA3131410A1 (pt) |
MX (1) | MX2021010349A (pt) |
WO (1) | WO2020175939A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102072059B1 (ko) * | 2019-02-28 | 2020-01-31 | 한국식품연구원 | 와이셀라 헬레니카 WiKim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
KR102328742B1 (ko) * | 2020-06-12 | 2021-11-22 | 숙명여자대학교산학협력단 | 신규한 와이셀라 시바리아 균주 및 이의 유청 발효물을 포함하는 비만 또는 지방간 질환의 예방 또는 개선용 식품 조성물 |
WO2022139532A1 (ko) * | 2020-12-23 | 2022-06-30 | 주식회사 리스큐어바이오사이언시스 | 와이셀라 헬레니카 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물 |
KR20220091429A (ko) | 2020-12-23 | 2022-06-30 | 주식회사 리스큐어바이오사이언시스 | 와이셀라 헬레니카 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100037310A (ko) * | 2008-10-01 | 2010-04-09 | 주식회사 비티엠 | 김치 유산균을 이용한 액상 건강보조식품의 제조방법 |
KR101130695B1 (ko) * | 2010-01-08 | 2012-04-02 | 우석대학교 산학협력단 | 오르니틴을 생산하는 능력이 있는 바이셀라 코리엔시스 ok1-6 균주, 상기 균주를 이용하여 오르니틴을 함유하는 김치의 제조방법 및 상기 방법에 의해 제조한 김치 |
KR20110134151A (ko) * | 2010-06-08 | 2011-12-14 | 주식회사 케이씨아이 | 혼합 균 배양물을 포함하는 피부 염증질환 개선제, 이를 포함하는 화장료 조성물 및 약제학적 조성물 |
US9468657B2 (en) * | 2010-06-08 | 2016-10-18 | Asahi Group Holdings, Ltd. | Lactic acid bacterium agent for improving lipid metabolism |
US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
KR20170000510A (ko) * | 2015-06-24 | 2017-01-03 | 주식회사 대유위니아 | 항비만 유산균의 발생을 위한 김치의 숙성방법 및 이것이 프로그래밍된 냉장고 |
KR101750850B1 (ko) * | 2015-09-08 | 2017-06-29 | 대한민국 | 바이셀라 코리엔시스의 특이적 프라이머 쌍 및 이를 이용한 바이셀라 코리엔시스의 검출방법 |
KR20170032815A (ko) | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물 |
JP7358001B2 (ja) * | 2018-02-16 | 2023-10-10 | イチビキ株式会社 | 乳酸菌、インターロイキン-22産生誘導剤、皮膚バリア機能増強剤 |
KR102072059B1 (ko) * | 2019-02-28 | 2020-01-31 | 한국식품연구원 | 와이셀라 헬레니카 WiKim0103를 포함하는 비만 또는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
-
2019
- 2019-02-28 KR KR1020190024255A patent/KR102072059B1/ko active IP Right Grant
-
2020
- 2020-02-27 JP JP2021550278A patent/JP7266110B2/ja active Active
- 2020-02-27 MX MX2021010349A patent/MX2021010349A/es unknown
- 2020-02-27 BR BR112021016865A patent/BR112021016865A2/pt not_active Application Discontinuation
- 2020-02-27 CA CA3131410A patent/CA3131410A1/en active Pending
- 2020-02-27 AU AU2020229728A patent/AU2020229728A1/en not_active Abandoned
- 2020-02-27 EP EP20763093.0A patent/EP3933030A4/en active Pending
- 2020-02-27 CN CN202080016283.2A patent/CN113508173A/zh active Pending
- 2020-02-27 WO PCT/KR2020/002844 patent/WO2020175939A1/ko unknown
- 2020-02-27 US US17/433,433 patent/US20220160796A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113508173A (zh) | 2021-10-15 |
MX2021010349A (es) | 2022-01-06 |
EP3933030A1 (en) | 2022-01-05 |
EP3933030A4 (en) | 2022-12-28 |
US20220160796A1 (en) | 2022-05-26 |
AU2020229728A1 (en) | 2021-09-30 |
WO2020175939A1 (ko) | 2020-09-03 |
CA3131410A1 (en) | 2020-09-03 |
JP7266110B2 (ja) | 2023-04-27 |
KR102072059B1 (ko) | 2020-01-31 |
JP2022522727A (ja) | 2022-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021016879A2 (pt) | Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo leuconostoc citreum wikim0104 | |
BR112021016865A2 (pt) | Composição para prevenção, melhora ou tratamento de obesidade ou doença hepática gordurosa compreendendo weissella hellenica wikim0103 | |
Sadaf et al. | Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells | |
ECSP21075909A (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
PE20211212A1 (es) | AGENTES DE ARNi PARA INHIBIR LA EXPRESION DE 17beta-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y METODOS DE USO | |
DOP2018000182A (es) | Benzamidas sustituidas con 1,3tiazol2ilo | |
CO2021000447A2 (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso | |
BR112016029781A2 (pt) | composições e métodos para inibir a expressão de gene de alfa-1 antitripsina | |
BR112017017178A2 (pt) | moduladores específicos de alelo de rodopsina de p23h | |
CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
Yang et al. | Methanol extract of Hopea odorata suppresses inflammatory responses via the direct inhibition of multiple kinases | |
CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
BR112022009409A2 (pt) | Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem | |
BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
BR112017020307A2 (pt) | método para inibir os sintomas associados com a ingestão de álcool, e, composição farmacêutica | |
Manaharan et al. | Antimetastatic and anti-inflammatory potentials of essential oil from edible Ocimum sanctum leaves | |
Valerio et al. | β-Sitosterol modulates TLR4 receptor expression and intracellular MyD88-dependent pathway activation in J774A. 1 murine macrophages | |
BR112023001957A2 (pt) | Composições e métodos para inibir expressão de lpa | |
BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
Handayani et al. | Brazilein in combination with cisplatin inhibit proliferation and migration on highly metastatic cancer cells, 4T1 | |
Oh et al. | 3, 5-Dicaffeoyl-Epi-Quinic acid isolated from edible halophyte Atriplex gmelinii inhibits adipogenesis via AMPK/MAPK pathway in 3T3-L1 adipocytes | |
BR112017007066A2 (pt) | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade | |
BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
Tu et al. | Pterostilbene attenuates ischemic stroke by modulating miR-21-5p/PDCD4 axis in vivo and in vitro | |
BR112019000783A2 (pt) | peptídeo eficaz na prevenção da doença causada por geminivírus, e método para usar o mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |